›
‹
- 1
- 2
- 3
- 4
- 5
Latest News
-
Executive Leadership Transition
After 14 years, Sue Kahn plans to step down. Read a letter from Sue and learn more about the position. Read More -
Make the Rare Diagnosis
Raising awareness about the importance of earlier diagnosis for Canavan, GM1, Sandhoff and Tay-Sachs. Read More -
Aspa's Canavan Clinical Trial
CANaspire Canavan gene therapy trial enrolling now at MGH in Boston. Read More
- 1
- 2
- 3
›
‹
NTSAD leads the worldwide fight to treat and cure Tay-Sachs, Canavan, GM1, and Sandhoff diseases by driving research, forging collaboration, and fostering community. Supporting families is the center of everything we do.
- Default
- Title
- Date
- Random
